Abstract

Additional SARS-CoV-2 vaccine doses: a little is better than none

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Decision letter: Study of efficacy and longevity of immune response to third and fourth doses of COVID-19 vaccines in patients with cancer: A single arm clinical trial
Mone Zaidi ... Jameel Iqbal
-
Mone Zaidi, et. al.Mone Zaidi ... Jameel Iqbal
09 Feb 2023
Editor's evaluation: Study of efficacy and longevity of immune response to third and fourth doses of COVID-19 vaccines in patients with cancer: A single arm clinical trial
Jameel Iqbal
-
Jameel IqbalJameel Iqbal
09 Feb 2023
Author response: Study of efficacy and longevity of immune response to third and fourth doses of COVID-19 vaccines in patients with cancer: A single arm clinical trial
Victor Thiruthuvanathan ... Maite Sabalza
-
Victor Thiruthuvanathan, et. al.Victor Thiruthuvanathan ... Maite Sabalza
27 Feb 2023
Hybrid immunity versus vaccine-induced immunity against SARS-CoV-2 in patients with autoimmune rheumatic diseases.
Aby Paul ... Nivin S
The Lancet. Rheumatology | VOL. 4
Aby Paul, et. al.Aby Paul ... Nivin S
22 Nov 2021
View more papers

More From: The Lancet Rheumatology

Paper Title
Journal
Date
Author
Identifying key health system components associated with improved outcomes to inform the re-configuration of services for adults with rare autoimmune rheumatic diseases: a mixed-methods study
Rosemary J Hollick ... Neil Basu
The Lancet Rheumatology | VOL. 6
Rosemary J Hollick, et. al.Rosemary J Hollick ... Neil Basu
01 Jun 2024
Protecting patients with SLE against herpes zoster: time for early proactive vaccine counselling
Laura Boekel
The Lancet Rheumatology | VOL. -
Laura BoekelLaura Boekel
01 May 2024
Immunogenicity of third dose COVID-19 vaccine strategies in patients who are immunocompromised with suboptimal immunity following two doses (OCTAVE-DUO): an open-label, multicentre, randomised, controlled, phase 3 trial
Carl S Goodyear ... Victoria Walker
The Lancet Rheumatology | VOL. 6
Carl S Goodyear, et. al.Carl S Goodyear ... Victoria Walker
01 May 2024
Immunogenicity, reactogenicity, and safety of two-dose adjuvanted herpes zoster subunit vaccine in patients with systemic lupus erythematosus in South Korea: a single-centre, randomised, double-blind, placebo-controlled trial
Jin Kyun Park ... Eun Bong Lee
The Lancet Rheumatology | VOL. -
Jin Kyun Park, et. al.Jin Kyun Park ... Eun Bong Lee
01 May 2024
View more papers